comparemela.com

Latest Breaking News On - டெர்மோட் மகவர்ந் - Page 1 : comparemela.com

Prometheus Biosciences to Host Virtual R&D Day for

Prometheus Biosciences to Host Virtual R&D Day for
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Study: COVID-19 vaccines safe for IBD patients

Patients with inflammatory bowel diseases (IBD) do not appear to have increased risk of side effects from the Pfizer or Moderna COVID-19 vaccines, according to a recent Cedars-Sinai study published online and upcoming in print in the American Journal of Gastroenterology.

Study finds COVID-19 vaccines safe for IBD patients

Los Angeles (June 8, 2021) IBDs, including Crohn s disease and ulcerative colitis, are chronic conditions that occur when the intestinal immune system becomes overreactive, causing chronic diarrhea and other digestive symptoms. In a published survey at the beginning of COVID-19 vaccine distribution, 70% of IBD patients reported concern about side effects from the vaccines. What we ve learned is that if you have IBD, the side effects you re likely to experience after a vaccine are no different than they would be for anyone else, said Gil Melmed, MD, corresponding author of the study and director of Inflammatory Bowel Disease Clinical Research at Cedars-Sinai. If you re being treated with advanced therapies such as biologics, these side effects might even be milder. So, don t let that be a reason that you re not getting vaccinated.

La vacuna contra la COVID-19 no produce más efectos secundarios en personas con enfermedad inflamatoria intestinal

La vacuna contra la COVID-19 no produce más efectos secundarios en personas con enfermedad inflamatoria intestinal
infosalus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from infosalus.com Daily Mail and Mail on Sunday newspapers.

Research roundup: Recent grants and publications for Emory faculty and staff

Rollins receives $6 million grant from Gilead’s HIV initiative Emory’s Rollins School of Public Health has announced a $6 million grant from Gilead Sciences, Inc. over three years to continue to build the capacity of organizations working on the frontlines of the HIV crisis in communities across the Southern United States. Emory will serve as one of four Gilead COMPASS coordinating centers alongside the Southern AIDS Coalition, the University of Houston Graduate College of Social Work, and Wake Forest School of Divinity to provide direct support to local community organizations to help mitigate the HIV epidemic in the South.  This is part of a second wave of funding from Gilead, manufacturer of antiretroviral therapies for HIV/AIDS. Emory’s COMPASS coordinating center has directly distributed more than $4.3 million to 104 community organizations, and is directed by Neena Smith-Bankhead, director of capacity building and community engagement. More information here.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.